Why does my pink current penny stock continue to decline in

New Post Public Reply Private Reply Replies (1) Message Board
Steel Reserve
2,144
Why does my pink current penny stock continue to decline in value?


"To make money (The company) on a pumped OTC [Market] [Stock], they have to have Losses not profits.

You cannot covert debt to free trading shares unless you post constant losses. That is why they lose more and more each quarter and keep the price dropping so only the company can sell shares at a profit but you all cannot.

There is no law saying they cannot add more shares and dilute and sell for less. Sure you lose money and as I have said many times, you Losing money is not illegal.

Dilution makes you lose money and adding shares to dilute is legal so there you have it.

All legal.

If the shares are $1.00 or $.0001 the company always makes money. And for a few at the company who sell the shares to make lots of money, 1000's of you have to lose money.

Keeping the stock slowly in decline makes it so no one will sell except for the company. When the shares are sold out, it’s over.

They know they can never sell 8 billion for $1 and raise $8,000,000,000 but they do know 1000s will spend $500 to $5000 no problem on shares that are $.01 or less, so to make at least $30 million they just have to sell more shares for less.

If they were a low-float, solid entity with 25,000,000 in the float at $.50 per share is $12,000,000. It’s the same being a diluted entity with 8,000,000,000 float at $.0015 is still $12,000,000

Which price do you think is easier to sell at? OTC investors want more for less, OTC pumped companies know this and are happy to accommodate.

The reason they chose dilution is, they know most will not buy a $.50 stock so it is easier to sell more people more shares for less cost.

Pumping a stock at $.002 will go to $.06 is a 30x gain, SURE it’s possible to have that happen but try and convince OTC investors the same percentage gain at $.50 will rise the same 30x to $15 per share. We know that won’t happen on the OTC

That is why almost all pumped OTC’s must dilute or they would have no shares to sell and they would only make some money on the initial pump then it would be over. The game is to keep going as long as people are buying the shares regardless of the price. To keep it going they add more shares.

The end product is to shut it down when the shares are gone, reverse merge, cancel all the old ticker shares, form a new ticker and do it all over again.

For every $.001 gain in share price over the current price, totals $100,000 on each 100,000,000 shares sold. When divided into a float with billions, that figure jumps to $1,000,000 per billion.

That is how this all works."

Source: Insert-tag-here

Sadly but true this is 90% of the OTC game.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 51

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 45

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 43

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 54

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 36

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 42

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 42

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading

Top 5 Most Recently Viewed Articles

Ackermans & van Haaren Invests $20 Million in New Venture Fund

Updated Category News Views 253

Ackermans & van Haaren Makes a Strategic Investment Acknowledging the evolving landscape of investment opportunities, Ackermans & van Haaren has made a notable commitment of 20 million US dollars to the second fund of Venturi Partners. This investment presents not only a financial backing but highlights the company's confidence in the innovative projects that Venturi...

Continue Reading
Parsons Corporation to Share Insights at Key Financial Conference

Updated Category News Views 285

Parsons Corporation's Upcoming Conference Presentation Parsons Corporation will soon take the stage at a significant financial event known as the Raymond James 46th Annual Institutional Investors Conference. This prestigious conference is an excellent opportunity for the company to engage with investors and provide insights into its strategic direction. Featured Speakers...

Continue Reading
Catawba Research Celebrates a Decade of Clinical Excellence

Updated Category News Views 192

Catawba Research is popping the champagne—10 years in the clinical research game. Yep, they’re not just another player; they’ve carved out a solid spot as a go-to Clinical Research Organization (CRO) on the global stage. Celebrating this milestone isn’t just about cake and confetti—it’s about recognizing their journey from being the underdog to taking...

Continue Reading
Insights into Royce Small-Cap Trust Performance and Strategy

Updated Category News Views 170

Understanding Royce Small-Cap Trust Royce Small-Cap Trust (NYSE: RVT) stands out as a notable closed-end fund within the spectrum of small-cap investments. Renowned for being one of the oldest and most established in this category, the fund attracts investors interested in capitalizing on the growth potential associated with smaller companies. Performance Overview As of...

Continue Reading
Hormel Foods Faces Profit Challenges Amid Commodity Cost Issues

Updated Category News Views 214

Hormel Foods Overview Hormel Foods Corporation (NYSE: HRL) has recently indicated that it may face a challenging year ahead, as the company grapples with various factors affecting profit recovery. The current market dynamics have led to notable changes in their earnings projections, which have raised concerns among investors. Recent Earnings Performance The company...

Continue Reading